» Articles » PMID: 30171256

The FOXC1/FBP1 Signaling Axis Promotes Colorectal Cancer Proliferation by Enhancing the Warburg Effect

Overview
Journal Oncogene
Date 2018 Sep 2
PMID 30171256
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant expression of Forkhead box (FOX) transcription factors plays vital roles in carcinogenesis. However, the function of the FOX family member FOXC1 in maintenance of colorectal cancer (CRC) malignancy is unknown. Herein, FOXC1 expression in CRC specimens in The Cancer Genome Atlas (TCGA) cohort was analyzed and validated using immunohistochemistry with a tissue microarray. The effect of FOXC1 expression on proliferation of and glycolysis in CRC cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. Our results showed that FOXC1 expression was higher in CRC specimens than in adjacent benign tissue specimens. Univariate survival analyses of the patients from whom the study specimens were obtained, and validated cohorts indicated that ectopic FOXC1 expression was significantly correlated with shortened survival. Silencing FOXC1 expression in CRC cells inhibited their proliferation and colony formation and decreased their glucose consumption and lactate production. In contrast, FOXC1 overexpression had the opposite effect. Furthermore, increased expression of FOXC1 downregulated that of a key glycolytic enzyme, fructose-1,6-bisphosphatase 1 (FBP1). Mechanistically, FOXC1 bound directly to the promoter regions of the FBP1 gene and negatively regulated its transcriptional activity. Collectively, aberrant FBP1 expression contributed to CRC tumorigenicity, and decreased FBP1 expression coupled with increased FOXC1 expression provided better prognostic information than did FOXC1 expression alone. Therefore, the FOXC1/FBP1 axis induces CRC cell proliferation, reprograms metabolism in CRCs, and constitutes potential prognostic predictors and therapeutic targets for CRC.

Citing Articles

Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer.

Xu L, Shen Y, Zhang C, Shi T, Sheng X J Cell Mol Med. 2025; 29(4):e70443.

PMID: 39993964 PMC: 11850098. DOI: 10.1111/jcmm.70443.


HIF1A-AS2 promotes the metabolic reprogramming and progression of colorectal cancer via miR-141-3p/FOXC1 axis.

Zhong X, Wang Y, He X, He X, Hu Z, Huang H Cell Death Dis. 2024; 15(9):645.

PMID: 39227375 PMC: 11372083. DOI: 10.1038/s41419-024-06958-2.


FOXC1 transcriptionally suppresses ABHD5 to inhibit the progression of renal cell carcinoma through AMPK/mTOR pathway.

Li J, Chen S, Xiao J, Ji J, Huang C, Shu G Cell Biol Toxicol. 2024; 40(1):62.

PMID: 39093497 PMC: 11297099. DOI: 10.1007/s10565-024-09899-w.


Dysregulated Forkhead Box (FOX) Genes Association with Survival Prognosis, Anti-tumor Immunity, and Key Targeting Drugs in Colon Adenocarcinoma.

Xie Q, Wang J, Peng X Arch Iran Med. 2024; 26(9):510-528.

PMID: 38310407 PMC: 10862056. DOI: 10.34172/aim.2023.77.


Elevated galectin-3 levels detected in women with hyperglycemia during early and mid-pregnancy antagonizes high glucose - induced trophoblast cells apoptosis via galectin-3/foxc1 pathway.

Deng Y, Jin H, Ning J, Cui D, Zhang M, Yang H Mol Med. 2023; 29(1):115.

PMID: 37626284 PMC: 10463409. DOI: 10.1186/s10020-023-00707-5.


References
1.
Zhu Y, Shi M, Chen H, Gu J, Zhang J, Shen B . NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Oncotarget. 2015; 6(25):21443-51. PMC: 4673277. DOI: 10.18632/oncotarget.4167. View

2.
Li Q, Wu J, Wei P, Xu Y, Zhuo C, Wang Y . Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition. Am J Cancer Res. 2015; 5(6):2022-34. PMC: 4529621. View

3.
Sun J, Li H, Huo Q, Cui M, Ge C, Zhao F . The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells. Oncotarget. 2016; 7(28):43534-43545. PMC: 5190042. DOI: 10.18632/oncotarget.9780. View

4.
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad E . High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000; 60(4):916-21. View